2020

/Tag:2020

Oramed Pharmaceuticals Inc. Prices Public Offering of Common Stock for Aggregate Proceeds of $21 Million

NEW YORK, Feb. 27, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ("Oramed" or "Company"), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the pricing of an underwritten public offering of 5,250,000 shares of its common stock [...]

2020-02-27T09:15:00+00:00 Categories: 新闻通稿|Tags: |

Oramed Patent in Europe to be Granted for Oral Delivery of Proteins

Protease inhibitor is a key component of platform technology that protects therapeutic proteins in the digestive system NEW YORK, Jan. 28, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) and (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery [...]

2020-01-28T07:25:00+00:00 Categories: 新闻通稿|Tags: |

Oramed Elects Dr. Alexander Fleming to Scientific Advisory Board

NEW YORK, Jan. 23, 2020 Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the addition of Dr. Alexander Fleming to its Scientific Advisory Board. Dr. Fleming is Founder and Executive [...]

2020-01-23T08:00:00+00:00 Categories: 新闻通稿|Tags: |

Oramed Appoints Dr. Jay Skyler to Scientific Advisory Board

NEW YORK, Jan. 21, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the addition of Jay Skyler, MD to its Scientific Advisory Board.      Dr. Skyler [...]

2020-01-21T07:25:00+00:00 Categories: 新闻通稿|Tags: |

Oramed Pharmaceuticals Issues Letter to Shareholders

NEW YORK, Jan. 9, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, is pleased to provide the following letter to shareholders from Chief Executive Officer Nadav Kidron. For a [...]

2020-01-09T07:00:00+00:00 Categories: 新闻通稿|Tags: |